Invasive Cervical Cancer Diagnosis and Management

Diagnostic Evaluation

The National Comprehensive Cancer Network recommends immediate cystoscopy and comprehensive staging evaluation for patients with invasive cervical cancer and hematuria, as this suggests bladder mucosal infiltration and upstages the disease to at least stage IVA cervical cancer 1
If bladder infiltration is confirmed histologically, this represents stage IVA disease requiring treatment per cervical cancer protocols, not CIN management 1
The American College of Obstetricians and Gynecologists defines true CIN 3 as non-invasive (preinvasive disease) 3, 4
The presence of microinvasion (≤3mm stromal invasion) or frank invasion indicates cervical cancer, not CIN, and requires staging workup including cystoscopy 1, 2

The National Comprehensive Cancer Network recommends referring patients with confirmed bladder involvement immediately to gynecologic oncology for stage IVA cervical cancer management 1
Treatment shifts from excisional procedures to definitive chemoradiation for patients with confirmed bladder involvement 1
Excisional treatment (LEEP, conization) is contraindicated once invasion is confirmed 1
For patients with CIN 3 and no bladder involvement, the American College of Obstetricians and Gynecologists recommends proceeding with diagnostic excisional procedure (cold-knife conization or LEEP) to definitively rule out occult invasion 3, 5, 2

The American College of Obstetricians and Gynecologists recommends follow-up with cervical cytology at 4-6 month intervals until 3 consecutive negative results, then annual cytology for patients with confirmed CIN 3 3, 5, 6
Alternative follow-up includes HPV DNA testing at 6-12 months post-treatment; if negative, proceed to annual cytology 3, 5, 6
The threshold for colposcopy during follow-up is any ASC or greater cytology result 3, 5, 6
Patients require indefinite surveillance, as recurrent disease can occur many years after treatment 3, 5, 6